Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications.

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Andrew J Goulian, Brielle Goldstein, Maarouf A Saad
{"title":"Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications.","authors":"Andrew J Goulian, Brielle Goldstein, Maarouf A Saad","doi":"10.3390/jcm14062061","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: Regenerative therapies have gained interest in orthopedic applications for their potential to enhance tissue regeneration, functional recovery, and pain modification. This review evaluates the clinical efficacy of platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), peptide-based treatments, and biomimetic materials in orthopedic care, with a focus on pain reduction and functional outcomes. <b>Methods</b>: A structured literature search in PubMed (January 2009-January 2025) identified 160 studies. After applying inclusion criteria prioritizing randomized controlled trials (RCTs) and clinical trials, 59 studies were included: 20 on PRP, 20 on MSCs, 10 on peptide therapies, and 7 on biomimetics. Data extraction focused on pain reduction and functional recovery, with risk of bias assessed using the Cochrane Risk of Bias (RoB) tool and ROBINS-I tool. A random-effects meta-regression analysis was conducted to evaluate the impact of therapy type, sample size, and risk of bias on reported pain reduction outcomes. <b>Results</b>: Meta-regression analysis identified MSC therapy as the most effective intervention for pain reduction (β = 8.45, <i>p</i> < 0.05), with PRP and peptide-based therapies showing moderate improvements, and biomimetic therapies demonstrating the lowest effect. PRP provided short-term pain relief, particularly in acute injuries and tendon repair, though inconsistencies in preparation methods limited success in chronic conditions. MSC therapies demonstrated cartilage regeneration and early osteoarthritis improvement, but high costs and ethical concerns remain barriers to widespread adoption. Peptide-based therapies and biomimetic materials, including engineered scaffolds and autologous protein solutions, showed promise for infection control and wound healing, though further research is needed to optimize dosing, delivery methods, and long-term safety. <b>Conclusions</b>: Regenerative therapies offer significant potential in orthopedic care, with MSC therapies demonstrating the most reliable regenerative effects, PRP providing short-term symptomatic relief, and peptide-based and biomimetic treatments emerging as promising adjuncts. However, standardized protocols and large-scale clinical trials are needed to establish long-term efficacy and improve clinical translation for broader adoption.</p>","PeriodicalId":15533,"journal":{"name":"Journal of Clinical Medicine","volume":"14 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943164/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcm14062061","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: Regenerative therapies have gained interest in orthopedic applications for their potential to enhance tissue regeneration, functional recovery, and pain modification. This review evaluates the clinical efficacy of platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), peptide-based treatments, and biomimetic materials in orthopedic care, with a focus on pain reduction and functional outcomes. Methods: A structured literature search in PubMed (January 2009-January 2025) identified 160 studies. After applying inclusion criteria prioritizing randomized controlled trials (RCTs) and clinical trials, 59 studies were included: 20 on PRP, 20 on MSCs, 10 on peptide therapies, and 7 on biomimetics. Data extraction focused on pain reduction and functional recovery, with risk of bias assessed using the Cochrane Risk of Bias (RoB) tool and ROBINS-I tool. A random-effects meta-regression analysis was conducted to evaluate the impact of therapy type, sample size, and risk of bias on reported pain reduction outcomes. Results: Meta-regression analysis identified MSC therapy as the most effective intervention for pain reduction (β = 8.45, p < 0.05), with PRP and peptide-based therapies showing moderate improvements, and biomimetic therapies demonstrating the lowest effect. PRP provided short-term pain relief, particularly in acute injuries and tendon repair, though inconsistencies in preparation methods limited success in chronic conditions. MSC therapies demonstrated cartilage regeneration and early osteoarthritis improvement, but high costs and ethical concerns remain barriers to widespread adoption. Peptide-based therapies and biomimetic materials, including engineered scaffolds and autologous protein solutions, showed promise for infection control and wound healing, though further research is needed to optimize dosing, delivery methods, and long-term safety. Conclusions: Regenerative therapies offer significant potential in orthopedic care, with MSC therapies demonstrating the most reliable regenerative effects, PRP providing short-term symptomatic relief, and peptide-based and biomimetic treatments emerging as promising adjuncts. However, standardized protocols and large-scale clinical trials are needed to establish long-term efficacy and improve clinical translation for broader adoption.

骨科再生疗法的进展:富血小板血浆、间充质干细胞、多肽疗法和仿生应用的综合综述。
背景/目的:再生疗法因其增强组织再生、功能恢复和疼痛调节的潜力而在骨科应用中引起了人们的兴趣。本综述评估了富血小板血浆(PRP)、间充质干细胞(MSCs)、肽基治疗和仿生材料在骨科护理中的临床疗效,重点关注疼痛减轻和功能结局。方法:在PubMed(2009年1月- 2025年1月)进行结构化文献检索,确定了160项研究。在应用随机对照试验(RCTs)和临床试验的优先纳入标准后,纳入了59项研究:20项关于PRP, 20项关于MSCs, 10项关于肽疗法,7项关于仿生。数据提取侧重于疼痛减轻和功能恢复,使用Cochrane风险偏倚(RoB)工具和ROBINS-I工具评估偏倚风险。进行随机效应meta回归分析,以评估治疗类型、样本量和偏倚风险对报告的疼痛减轻结果的影响。结果:meta -回归分析发现MSC治疗是缓解疼痛最有效的干预措施(β = 8.45, p < 0.05), PRP和基于肽的治疗显示中度改善,仿生治疗显示最低效果。PRP可以短期缓解疼痛,特别是在急性损伤和肌腱修复中,尽管制备方法的不一致性限制了慢性疾病的成功。MSC疗法显示出软骨再生和早期骨关节炎的改善,但高昂的成本和伦理问题仍然是广泛采用的障碍。肽类疗法和仿生材料,包括工程支架和自体蛋白溶液,显示出感染控制和伤口愈合的希望,尽管需要进一步的研究来优化剂量、给药方法和长期安全性。结论:再生疗法在骨科护理中具有巨大的潜力,MSC疗法显示出最可靠的再生效果,PRP提供短期症状缓解,基于肽和仿生的治疗成为有希望的辅助疗法。然而,需要标准化的方案和大规模的临床试验来建立长期疗效,并改善临床转译以供更广泛的采用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Medicine
Journal of Clinical Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
5.70
自引率
7.70%
发文量
6468
审稿时长
16.32 days
期刊介绍: Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals. Unique features of this journal: manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes. There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信